Craig Johnson Net Worth

The estimated Net Worth of Craig A Johnson is at least $1.32 millió dollars as of 8 July 2022. Mr. Johnson owns over 12,000 units of Mirati Therapeutics Inc stock worth over $704,400 and over the last 14 years he sold MRTX stock worth over $13,613. In addition, he makes $605,171 as Independent Director at Mirati Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Johnson MRTX stock SEC Form 4 insiders trading

Craig has made over 9 trades of the Mirati Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 12,000 units of MRTX stock worth $47,160 on 8 July 2022.

The largest trade he's ever made was exercising 17,000 units of Mirati Therapeutics Inc stock on 29 January 2019 worth over $147,050. On average, Craig trades about 1,125 units every 22 days since 2011. As of 8 July 2022 he still owns at least 12,000 units of Mirati Therapeutics Inc stock.

You can see the complete history of Mr. Johnson stock trades at the bottom of the page.

Craig Johnson biography

Craig A. Johnson serves as Independent Director of the Company. Mr. Johnson has served as a member of our Board of Directors since September 2013. He also serves as a director of Heron Therapeutics, Inc., a director of La Jolla Pharmaceutical Company and a director of Odonate Therapeutics, Inc. Mr. Johnson served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018, a director of Adamis Pharmaceuticals Corporation from 2011 to 2014 and a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. and, from 2009 to 2010, as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

What is the salary of Craig Johnson?

As the Independent Director of Mirati Therapeutics Inc, the total compensation of Craig Johnson at Mirati Therapeutics Inc is $605,171. There are 8 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.

How old is Craig Johnson?

Craig Johnson is 58, he's been the Independent Director of Mirati Therapeutics Inc since 2013. There are 10 older and 8 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.

What's Craig Johnson's mailing address?

Craig's mailing address filed with the SEC is C/O MIRATI THERAPEUTICS, INC., 3545 CRAY COURT, SAN DIEGO, CA, 92121.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... és Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.

What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Complete history of Mr. Johnson stock trades at Adamis Pharmaceuticals Corp, Heron Therapeutics Inc, La Jolla Pharmaceutical Co, Mirati Therapeutics Inc és Odonate Therapeutics Inc

Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include:

• Charles Baum,
  President, Chief Executive Officer, Director
• James Christensen,
  Executive Vice President, Chief Scientific Officer
• Faheem Hasnain,
  Chairman of the Board
• Julie Cherrington,
  Independent Director
• Dr. Charles M. Baum M.D., Ph.D.,
  Founder, Pres, Head of R&D and Director
• Dr. James G. Christensen Ph.D.,
  Chief Scientific Officer
• Benjamin J. Hickey M.B.A.,
  Chief Commercial Officer
• Bruce Carter,
  Independent Director
• Craig Johnson,
  Independent Director
• Henry Fuchs,
  Independent Director
• Maya Martinez-Davis,
  Independent Director
• Michael Grey,
  Independent Director
• Aaron Davis,
  Independent Director
• Temre Johnson,
  Director, Investor Relations and Corporate Communications
• Joseph Leveque,
  Chief Medical Officer
• Benjamin Hickey,
  Executive Vice President, Chief Commercial Officer
• Daniel Faga,
  Chief Operating Officer, Executive Vice President
• Michael E. Paolucci,
  Chief People Officer
• Laurie D. Stelzer,
  Chief Financial Officer
• Ryan Asay,
  VP & Head of Corp. Affairs
• Dr. Kelly Covello Ph.D.,
  VP & Head of Medical Affairs
• Kristin Gustafson,
  Chief HR Officer
• Reena R. Desai,
  Gen. Counsel & Corp. Sec.
• Vickie S. Reed,
  Sr. VP & Chief Accounting Officer
• David D. Meek,
  CEO & Director
• Rodney W Lappe,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer,
  10% owner
• Asset Management Inc. Boxer,
  10% owner
• Mark J Gergen,
  Exec. VP and COO
• Ltd. Braslyn,
  10% owner
• William R Ringo,
  Director
• Christopher C. Lemasters,
  EVP, Chief Business Officer
• Laurie Stelzer,
  Chief Financial Officer
• Capital, Llc Boxer Asset Ma...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Capital Advisors Llc Aghaza...,
  
• Capital, Llc Braslyn Ltd. B...,
  
• Healthcare Master Fund Ltd ...,
  
• Thirteen Inc. Tuesday,
  10% owner
• Capital, Llc Boxer Asset Ma...,
  
• Maria E Martinez,
  
• Neil Reisman,
  10% owner
• Investors, Llc Mva,
  10% owner
• Shehan Bharatha Dissanayake,
  10% owner
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital Management Ltd.Bras...,
  
• Capital Partners Lptang Kev...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Martin Godbout,
  Director
• Jamie A Donadio,
  VP of Finance
• Advisors Llc Orbi Med Capit...,
  
• Felixbaker Julian Baker Bro...,
  
• Vickie S Reed,
  SVP, Chief Accounting Officer
• Isan Chen,
  EVP, Chief Medical Officer
• Shalini Sharp,
  
• Capital, Llc Boxer Asset Ma...,
  
• Ltd.Lewis Joseph Braslyn,
  
• Capital, Llc Boxer Asset Ma...,
  
• David D. Meek,
  Chief Executive Officer
• Jamie Christensen,
  EVP & Chief Scientific Officer
• John B Moriarty,
  Chief Legal Officer
• Carol Giltner Gallagher,
  
• Alan B. Sandler,
  Chief Medical Officer
• Aaron I. Davis,
  
• Capital, Llc Boxer Asset Ma...,